Antiviral Agents
Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, a...
Uloženo v:
| Médium: | Online |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Témata: | |
| On-line přístup: | ONIX_20210501_9783039289530_715 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1869516523080515584 |
|---|---|
| collection | Directory of Open Access Books |
| description | Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents. |
| format | Online |
| id | doab-20.500.12854ir-68969 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-689692024-03-28T03:33:14Z Antiviral Agents Adamson, Catherine Zika virus nucleoside analogues antiviral agents NS5 prodrugs ProTides neural stem cells RNA-dependent RNA polymerase cytomegalovirus latent infection TALEN Surveyor nuclease mutation detection assay ie-1 gene quantitative real-time PCR Epstein–Barr virus herpes viruses lytic gene expression Burkitt lymphoma cells clozapine antipsychotic drug antiviral drug enteroviruses coxsackievirus B4 persistent infection fluoxetine resistance mutations herpes B virus macacine herpesvirus-1 genistein flavonoids acyclovir ganciclovir Plantago asiatica Clerodendrum trichotomum RSV therapeutic effects acteoside human antimicrobial peptides antiviral strategies defensins cathelicidins hepcidins transferrins influenza A virus brevilin A antiviral sesquiterpene lactone replication PRRSV polyethylenimine PEI virion internalization endocytosis HIV pediatrics Ethiopia pre-treatment drug resistance combination antiretroviral therapy (cART) dried plasma spots dried blood spots sphingolipids glycosphingolipids viruses lipid biosynthesis flavivirus Japanese encephalitis virus furin inhibitor precursor membrane protein measles virus central nervous system tropism treatments porcine reproductive and respiratory syndrome virus ginsenoside Rg1 antiviral activity pro-inflammatory factor NF-κB signaling pathway acute/latent infection congenital infection antiviral agent therapeutic strategies nucleic acid-based therapeutic approach HCMV vaccine adoptive cell therapy Rev response element chemical footprinting SHAPE drug discovery branched peptides herpesvirus immediate-early IE1 IE2 ribozyme RNA interference CRISPR/Cas small molecule orthohantavirus phenyl-benzotriazoles C-FRA Porcine circovirus type 2 epigallocatechin gallate heparan sulfate antiviral effect virus attachment microvirin lectin human immunodeficiency virus hepatitis C virus antiviral inhibitor non-immunogenic viral entry protein drugs LUMS1 oleanane-type derivatives influenza A virus (IAV) virus entry inhibitors hemagglutinin (HA) n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Antiviral agents are used for the treatment of viral diseases. Antiviral drugs have been successfully developed and used clinically for a limited number of important human viral diseases notably caused by human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), herpes, and influenza viruses. Despite the successes of these antiviral drugs, issues with drug resistance and toxicity remain challenging. These challenges are driving research to identify new drug candidates and to investigate novel drug targets to develop new mechanistic drug classes. Antiviral agents are not available against many viruses that cause human disease and economic burdens; in particular, the development of antiviral agents against emerging, re-emerging, and neglected viruses is increasingly becoming a priority. This book includes six review articles that discuss new antiviral strategies. The reviews either discuss advances relating to a specific virus or new therapeutic targets and approaches. The book includes 15 original research articles reporting new antiviral agents against a variety of clinically and economically important viruses and studies into the prevalence or acquisition of drug resistance. Overall, this book is an exciting collection of new research and ideas relating to the development of antiviral agents. 2021-05-01T15:34:25Z 2021-05-01T15:34:25Z 2020 book ONIX_20210501_9783039289530_715 9783039289530 9783039289547 https://directory.doabooks.org/handle/20.500.12854/68969 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/2737 https://mdpi.com/books/pdfview/book/2737 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03928-954-7 10.3390/books978-3-03928-954-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039289530 9783039289547 386 Basel, Switzerland open access |
| spellingShingle | Zika virus nucleoside analogues antiviral agents NS5 prodrugs ProTides neural stem cells RNA-dependent RNA polymerase cytomegalovirus latent infection TALEN Surveyor nuclease mutation detection assay ie-1 gene quantitative real-time PCR Epstein–Barr virus herpes viruses lytic gene expression Burkitt lymphoma cells clozapine antipsychotic drug antiviral drug enteroviruses coxsackievirus B4 persistent infection fluoxetine resistance mutations herpes B virus macacine herpesvirus-1 genistein flavonoids acyclovir ganciclovir Plantago asiatica Clerodendrum trichotomum RSV therapeutic effects acteoside human antimicrobial peptides antiviral strategies defensins cathelicidins hepcidins transferrins influenza A virus brevilin A antiviral sesquiterpene lactone replication PRRSV polyethylenimine PEI virion internalization endocytosis HIV pediatrics Ethiopia pre-treatment drug resistance combination antiretroviral therapy (cART) dried plasma spots dried blood spots sphingolipids glycosphingolipids viruses lipid biosynthesis flavivirus Japanese encephalitis virus furin inhibitor precursor membrane protein measles virus central nervous system tropism treatments porcine reproductive and respiratory syndrome virus ginsenoside Rg1 antiviral activity pro-inflammatory factor NF-κB signaling pathway acute/latent infection congenital infection antiviral agent therapeutic strategies nucleic acid-based therapeutic approach HCMV vaccine adoptive cell therapy Rev response element chemical footprinting SHAPE drug discovery branched peptides herpesvirus immediate-early IE1 IE2 ribozyme RNA interference CRISPR/Cas small molecule orthohantavirus phenyl-benzotriazoles C-FRA Porcine circovirus type 2 epigallocatechin gallate heparan sulfate antiviral effect virus attachment microvirin lectin human immunodeficiency virus hepatitis C virus antiviral inhibitor non-immunogenic viral entry protein drugs LUMS1 oleanane-type derivatives influenza A virus (IAV) virus entry inhibitors hemagglutinin (HA) n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Antiviral Agents |
| title | Antiviral Agents |
| title_full | Antiviral Agents |
| title_fullStr | Antiviral Agents |
| title_full_unstemmed | Antiviral Agents |
| title_short | Antiviral Agents |
| title_sort | antiviral agents |
| topic | Zika virus nucleoside analogues antiviral agents NS5 prodrugs ProTides neural stem cells RNA-dependent RNA polymerase cytomegalovirus latent infection TALEN Surveyor nuclease mutation detection assay ie-1 gene quantitative real-time PCR Epstein–Barr virus herpes viruses lytic gene expression Burkitt lymphoma cells clozapine antipsychotic drug antiviral drug enteroviruses coxsackievirus B4 persistent infection fluoxetine resistance mutations herpes B virus macacine herpesvirus-1 genistein flavonoids acyclovir ganciclovir Plantago asiatica Clerodendrum trichotomum RSV therapeutic effects acteoside human antimicrobial peptides antiviral strategies defensins cathelicidins hepcidins transferrins influenza A virus brevilin A antiviral sesquiterpene lactone replication PRRSV polyethylenimine PEI virion internalization endocytosis HIV pediatrics Ethiopia pre-treatment drug resistance combination antiretroviral therapy (cART) dried plasma spots dried blood spots sphingolipids glycosphingolipids viruses lipid biosynthesis flavivirus Japanese encephalitis virus furin inhibitor precursor membrane protein measles virus central nervous system tropism treatments porcine reproductive and respiratory syndrome virus ginsenoside Rg1 antiviral activity pro-inflammatory factor NF-κB signaling pathway acute/latent infection congenital infection antiviral agent therapeutic strategies nucleic acid-based therapeutic approach HCMV vaccine adoptive cell therapy Rev response element chemical footprinting SHAPE drug discovery branched peptides herpesvirus immediate-early IE1 IE2 ribozyme RNA interference CRISPR/Cas small molecule orthohantavirus phenyl-benzotriazoles C-FRA Porcine circovirus type 2 epigallocatechin gallate heparan sulfate antiviral effect virus attachment microvirin lectin human immunodeficiency virus hepatitis C virus antiviral inhibitor non-immunogenic viral entry protein drugs LUMS1 oleanane-type derivatives influenza A virus (IAV) virus entry inhibitors hemagglutinin (HA) n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| topic_facet | Zika virus nucleoside analogues antiviral agents NS5 prodrugs ProTides neural stem cells RNA-dependent RNA polymerase cytomegalovirus latent infection TALEN Surveyor nuclease mutation detection assay ie-1 gene quantitative real-time PCR Epstein–Barr virus herpes viruses lytic gene expression Burkitt lymphoma cells clozapine antipsychotic drug antiviral drug enteroviruses coxsackievirus B4 persistent infection fluoxetine resistance mutations herpes B virus macacine herpesvirus-1 genistein flavonoids acyclovir ganciclovir Plantago asiatica Clerodendrum trichotomum RSV therapeutic effects acteoside human antimicrobial peptides antiviral strategies defensins cathelicidins hepcidins transferrins influenza A virus brevilin A antiviral sesquiterpene lactone replication PRRSV polyethylenimine PEI virion internalization endocytosis HIV pediatrics Ethiopia pre-treatment drug resistance combination antiretroviral therapy (cART) dried plasma spots dried blood spots sphingolipids glycosphingolipids viruses lipid biosynthesis flavivirus Japanese encephalitis virus furin inhibitor precursor membrane protein measles virus central nervous system tropism treatments porcine reproductive and respiratory syndrome virus ginsenoside Rg1 antiviral activity pro-inflammatory factor NF-κB signaling pathway acute/latent infection congenital infection antiviral agent therapeutic strategies nucleic acid-based therapeutic approach HCMV vaccine adoptive cell therapy Rev response element chemical footprinting SHAPE drug discovery branched peptides herpesvirus immediate-early IE1 IE2 ribozyme RNA interference CRISPR/Cas small molecule orthohantavirus phenyl-benzotriazoles C-FRA Porcine circovirus type 2 epigallocatechin gallate heparan sulfate antiviral effect virus attachment microvirin lectin human immunodeficiency virus hepatitis C virus antiviral inhibitor non-immunogenic viral entry protein drugs LUMS1 oleanane-type derivatives influenza A virus (IAV) virus entry inhibitors hemagglutinin (HA) n/a thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| url | ONIX_20210501_9783039289530_715 |